Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma

Multiple myeloma (MM) is an aggressive incurable plasma cell malignancy with a median life expectancy of less than seven years. Antibody-based therapies have demonstrated substantial clinical benefit for patients with hematological malignancies, particular in B cell Non-Hodgkin’s lymphoma. The lack of immunotherapies specifically targeting MM cells led us to develop a human-mouse chimeric antibody directed against the B cell maturation antigen (BCMA), which is almost exclusively expressed on plasma cells and multiple myeloma cells.

Source: Molecular Oncology - March 31, 2015 Category: Cancer & Oncology Authors: Felix Oden, Stephen F. Marino, Janko Brand, Susanne Scheu, Cathleen Kriegel, Daniel Olal, Anna Takvorian, Jörg Westermann, Buket Yilmaz, Michael Hinz, Oliver Daumke, Uta E. Höpken, Gerd Müller, Martin Lipp Source Type: research